¬u²±¦~³ø´¦ÅS,2012¦~¥þ²y«e10¤jÃÄ«~,²Ä¤@¦WGSK,¨ä®ð³ÝÃĦ~¾P°âÃB¬°89»õ¬ü¤¸¡C²Ä¤G¦W¬°Abbot,¨äÃþ··ÃÃö¸`ª¢ÃĦ~¾P°âÃB¬°85»õ¬ü¤¸,³o¨â¶µÃĬҬ°¬u²±¥D¤O²£«~,¥]¬AAnti-Cemx, Xolair, Anti-IL6. ©Ò¥H¤@°_´Á«Ý¦~©³¨Îµ¡C
´CÅé©ñ§Q¦h
¤½¥q«°T¼á²M
¤j·§´N¬O°ªÂI¤F
¯E¹©µoªí©óASCO½×¤åAbstractŪ«á¤ß±o:
a titer ≥ 1:160 &nonresponders:
PFS: HR, 0.52 [95% CI, 0.37-0.71] P< .0001
OS : HR, 0.52 [95% CI, 0.29-0.92] P = .025
Æ[¹îP value< 0.0001 Extremely significant ¡C
Globo H¬°¥Ø«e°ß£¸¥uªí²{¦bcancer cell ¤£ªí²{¦b¥¿±`²ÓM¤W¡A¦]¦¹¤£¹³Herceptin·|¤Ö³¡¤À¶Ë®`¨ì¥¿±`²ÓM¡A³Ì¥i¶Q¬OGlobo H vaccine¥i¦P®ÉªvÀø©Ò¦³ER(+),PR(+),HER2,Triple(-)¡C¥Ø«e°ê»Ú¤jÃļtµL¤H¯à¤Î¡C¯f¤H¤£»Ý¹³PD-L1»Ý¨Æ¥ý¿z¿ï¡A¦¹¬Ì]§ÜÅé¥i¿ëÃÑglobe H,¤Îstem cell ¤Wssea 3 and ssea 4¡A³o¤TºØÁÞ¤À¤lGH series§Üì¦bÀù²ÓM¡BÀù·F²ÓM¤W¤À¥¬±µªñ100%¡A©Ò¥H±q¹êÅçµ²ªG±oª¾¡A¥un²£¥Í¦³®Ä§ÜÅétiter ≥ 1:160 ¡A§Y¦³·¥ÅãµÛ©ÊÀøªk¡C
¥Í§ÞªÑ§Y±N§_·¥®õ¨Ó¡A³ß¨ÆÁ{ªù¡C¬u²±ªñ´Á¦¨¥æ¶q«ùÄò©ñ¤j¡A¦b¦b»¡©ú¦³¨Æµo¥Í¡C¬u²±©Î³\¤]±N³¶«Ì¤¤¿ïÀò±o°ê»Ú¤jÃļt«C·ý¡A±ÂÅv¦¨¥\¡C«¥Ì«ø¥Ø¥H«Ý¡C
udn.com/news/story/7254/2612564
µ´¤j¦h¼ÆÀ³¸Ó³£¿ù¹L¤F
¦pªG¥¼¨Ó¦³¥D¤É¬qªº¸Ü
§Æ±æ¤j®a³£¯à¦³¾÷·|°Ñ»P
¤£ª¾¹Dµo¥Í¬Æ»ò¤j®a³£¤£ª¾¹Dªº¨Æ¤F
¤S©Î³\¤°»ò¨Æ³£¨S¦³
¥u¬O³æ¯Â¥D¤Oª£§@¬°¤F¦Û¤v¸Ñ®M¦Ó¤w
µ²ªG³y¦¨¤µ¤Ñì©l¬u²±ªÑªF¨ü·l¡A¤Wº¦ÁÙ³Q©ì²Ö¡ã
ì©l¬u²±¤pªÑªFªºÅv¯q¦ó¦b°Ú¡ã
Y¬Ý»ùÈ¡A¥H«eªº¬u²±¡A¤]À³¸Ón¦³3¦ì¼ÆªºªÑ»ù¡A¬°¦ó¤@ª½¶^¨ì2¢æ¡H´N¬O¦]¬°ÃD§÷¥¼¨ì¡A¥D¤O¤£«æµÛ¶i³õ¡CªO¤WªºªB¤Í¡AÀ³¸Ó¤]µ¥¤F¨â¤T¦~¡A¤µ¦~¤]³\´N§Öµ¥¨ì±ÂÅv¡A²{¦bIµÛ¨ó©M¡A¨ì®É¯uªº±ÂÅv¡AªÑ»ù¸±o°_¨Ó¶Ü¡H
²{¦bÁÙ¤£ª¾¹D³o¥D¤Oªº¤ßºA¬O¦p¦ó¡H¬O¤£¬O¤]¬O¬Ý·Ç±ÂÅv®É¶¡®t¤£¦h¡A¶}©l¶i³õ½ä¤@§â¡A¦ý±ÂÅvY¬OÁÙ¬O»»»»µL´Á¡A¥D¤O¤@°h³õ¡AÁÙ¬O·|¶^¦^°_º¦ÂI.......
2016.4¤ëAbbVie¯{¤U¹dÃB¤Ñ»ù102»õ¬ü¤¸¦¬ÁÊStemcentrx¤½¥q©ãª`Àù¯g·F²ÓM
Stemcentrx¤½¥q¦³¤Ïú试验©Ê·s药¡A¨ä¤¤¤TÏú¤w¦b¦´Á临§É试验¤¤¨ú±o¤F¥i³ßªº结ªG¡A¥t两Ïú¤]¥¿处¤_I´Á»PII´Á临§É试验阶¬q.
Y¸s¯qª÷¹©¨º¦ì¤j¤á°±¤î½æ¡AÀ³¸Ó·|©Ô§ó§Ö¡A³o°}¤l¥L¨C¤Ñ½æ50±i¡A¬Q¤Ñ¶X¶Õ½æ186¡A¨S·N¥~¡A¤µ¤ÑÀ³¸Ó·|½æ300±i¥H¤W§a¡C
¦]¬°®õºÖ³Ìªñªº·s»D¡AÅý§Ú·Q¨ì¬°¦ó¨ó©M·sÃĤ£¦Û¤v¤W¿³Âd¡A¦Ó¬O¸ò¬u²±¦X¨Ö¡Aµª®×À³¸Ó´N¬O³oÓ
¡yÃÒ¥æ©Ò26¤é³q¹L®õºÖ-KY¤W¥«¥Ó½Ð®×¡A¨ä¤¤²Ä¤T¶µ¡An¨D¤½¥q¤§¸³¨Æ¡B«ùªÑ¶W¹L¤wµo¦æªÑ¥÷Á`ÃB¦Ê¤À¤§5¤§ªÑªF¡BÁ`¸g²z¤Î¬ãµo¥DºÞ¡A©Ó¿Õ¨ä¨Ì¥»¤½¥q¡u¦³»ùÃÒ¨é¤W¥«¼f¬d·Ç«h¡v²Ä28±ø¤§9²Ä2¶µ³W©w´£¥æ¶°¤¤«OºÞ¤§ªÑ²¼¡AÀ³¦Û¤W¥«¶R½æ¶}©l¤é°_©¡º¡1¦~«á¡A¥B¸Ó¤½¥q¤½§i¥Ó³ø¤§°]°È³ø§iµ|«e·l¯q¬°¥¿¼Æ¡A©l±o»â¦^2¤À¤§1¡A«S±o»â¦^¶°¤¤«OºÞªÑ²¼¶}©l¤é°_©¡º¡1¦~«á©l±o¥þ¼Æ»â¦^¡C¡z
¦pªG·Qn¿³Âd¡A¨S°ÝÃD¡A°ÝÃD¬O¤£¯à½æªÑ²¼¡A¹ï¬Y¨Ç¤jªÑªF¦Ó¨¥¡A¿³Âd´N¨S·N¸q¤F¡A¦Ó¨ó©Mnµ¥¨ì¯àÀò§Q¡A¨S3-5¦~¬O¤£¥i¯àªº¨Æ¡A¥Î¨Öªº°¨¤W´N¥i¥H½æ¡C
¦Ñ¹ê»¡¡A¦X¨Ö§Ú¬O¨S·N¨£¡A¦ý¥Î³o»ù®æ¨Ö¡A®Ú¥»¬OÄ묹¬u²±¤pªÑªFªºÅv¯q
¨ØªA
¦]µØ18~26
§C»ù¥ÍÂåªÑ·|ÃþªÑ½ü°Ê¶Ü¡H
¥H¤W½Ð¤Å°Ñ¦Ò
¨º»ò¬u²±»P²Ä3²Õ¤H°¨ÁÙ¦P¨B¶}µo§ÜC£`mX¬Ì]»Panti-EMPD¬Ì]?
:¥»¤½¥q«Ø¥ß¤§§ÜC£`mXªvÀø¹L±Ó©Ê¯e¯f·sÃħ޳N¥¥x¡A°£¶i¦æAnti-C£`mX ³æ
®è§ÜÅéFB825¶}µo¥~¡A¦P¨B¶}µo§ÜC£`mX¬Ì]¡A¥»¦¸³q¹L¬ü°ê±M§Q¦WºÙ¬°¡uC£`mX
peptides for inducing immune responses to human mIgE on B lymphocytes¡v¡A
±M§QÃҮѦr¸¹8,974,794¡C
³o¤@½g2016.7¤ë²Ä4²Õ¹Î¶¤ªF¨Ê²z¬ìµoªí¦bNature Immunology:
Autonomous membrane IgE signaling prevents IgE-memory formationµy¨£ºÝÙ.
....Our findings reveal an autonomous mIgE signaling mechanism that normally prevents IgE+ Bmem and LLPC formation
http://www.nature.com/ni/journal/v17/n9/full/ni.3508.html
ñ´»CDA¦³¨S¦³Ã¹¤ó»P¿ÕµØ???
§äµo¨¥¤H¥H³Ì¦Ã±¸pªºG®a....ÂPÂP¬Ý!
Xolair¥Ñù¤óRoche(¬ü°ê¥«³õ...)©M¿ÕµØNovartis(¼Ú¬w¥«³õ)Áp¦X¾P°â.
ªñ¦~xolair±M§Q³°Äò¨ì´Á,ù¤ó©M¿ÕµØn·Q¤è³]ªk¾d©T®ð³ÝëC³Â¯l¥«³õ,¦]¦¹QuilizumabÁ{§É®É·í¥H®ð³ÝëC³Â¯l¬°Àu¥ý.
Y2®a³£¦³Ã±CDA,¨º»ò²Õ¦XÀøªkFB825+ xolair´N¬O¤@¿ï¶µ,°£¤FÀ±¸Éxolair¦]Ige¤ô¥»PÅ髪º¨î±ø¥ó¦ÓµLªk¬I¥´ªº±wªÌ.
¤]¯à¹ïXolair¥Íª«¬Û¦üÃħΦ¨«Ì»Ù.
©êºp,¤Ö¥´¤@¦r¤F
¬O§_³]©wªº°Ñ¼Æ,±ø¥ó·|¼vÅTµ²ªG?
´N¦³½ÐC¸òR¤j¸ò¤j®a¸ÑªR¸ÑªR
¦]¤W¦¸¤½¥q¦³´£¨ì,ù¤ó³]©wªº¤£¬O«Ü¦n
¥Í§Þ§Ú¬Oªù¥~º~¡A¦ý´¶Ã¹¤j²³¦³½Ö¨º»ò¼F®`¥i¥H»¡±o·ÇÁÙ¤£¬O¸ÕµÛ°µ¨«µÛÁ@¡A§ó¦óªp§ÚÌÁÙ¦³¤¤¬ã°|¡B¥x¤j¡B¡Bµ¥±M·~»â°ì¹Ù¦ñ¥B¦³¶°¹Î§ë«H©Mª¾¦W¤j©@¬Û¦ñÀH¡C
³o¤G®a¤£¨ã¦³¤¬¸É©Ê?
¦b¦P¤@®a¤½¥qªºû¤u·|·d¬£¨t°«ª§,¦óªp¬O¤£¦P®aû¤u?
·R´þÀù¯g¯à¦³²Õ¦XÀøªk,¦Û¨§K¬Ì¯e¯f´N¦æ¤£³q?
Ige¤ô¥¶W¹L¨î¤£¯à¬I¥´?
¤½¥qºô¶©ú¸üFB825©MXolair(©ÎFB317)¦X¥Î¡Aµo´§¬Û¼¥\®Ä¡A¨Ã´î§CXolairªº¥Î¶q¡A¤Î°§C¹L±Ó±wªÌ»PÂåÀø¨t²Îªº¸gÀÙt¾á
6/30°ê®õªk»¡·|²³ø¤¤««×¹L±Ó©Ê®ð³Ý¤´¦CªvÀø¾AÀ³¯g,¦bP2aµ²ªG¥X¨Ó©ÎFB317®³¨ìÃÄÃÒÀ³¸Ó´N·|Á{§É²Õ¦XÀøªk?
Anti-M1¡¦ / Anti-C£`mX/ anti-EMPD ¦U¦ÛºÙ¸¹.
2017¦~²Ä3²Õ¤Hªº³ø§i:
¡K. Based on our in vitro findings, we propose that Ce3 targeting could be combined with EMPD targeting to further exploit possible additive effects similar to what was observed with our in vitro combinations ( Fig. 2C). Our observation might spur future clinical modalities, including established anti-IgE therapies. As an example, the obvious group of allergic asthma patients that are currently not eligible to Omalizumab therapy due to excessive IgE levels and/or body weight ( Cohen et al., 2014 ; Liour et al., 2016) might benefit from such combined anti-IgE therapies involving soluble IgE targeting and human EMPD IgE targeting
http://www.sciencedirect.com/science/article/pii/S0022175917300650
¤j·§¬O¨ó©M¿³Âd«ÜÃø¡A¨Ö¦¨¬u²±ªÑ²¼´N¯à½æ¤F¡A
¤S¦h¤@°ïªÑ²¼¯à½æ¿ú¤F
ÃĪ«§@¥Î¾÷¨î¡A¤W¤FÄ_¶Qªº¤@½Ò¡A´CÅé¤@¸ô³ø³ß¤£³ø
¼~¡AªÑ»ù¤Ï¬M¤@®a¤½¥qªº»ùÈ¡A¦A¶Ìªº¤H¤]µoı¤£¹ï
¤F¡C
©Ò¥HÂX¤j¾AÀ³¯g,¥Ó½Ð©t¨àÃÄ
¬°FB825¥t´M¥X¸ô
´N¬ì¾Ç¤W¨Ó±´°Q¡A§Ú¬O½Ö¨Ã¤£¼vÅT§ÜÅ骺§@¥Î¾÷¨î¡C
¤ÞzAnti-IgEÃĪ«ªvÀø¡uºC©ÊëC³Â¯l¡vªº¾÷¨î±´°Q¸Ìªº¤º®e¡A
°ò¥»¤W¡A¤j³¡¥÷ªº¹L±Ó²{¶H¡A³£¨Ó¦Û¤HÅ餺ªº§K¬Ì²ÓMIgE¤À¤l¡C¦b¸ûì©lªºÀô¹Ò¸Ì¡A¦]¬°¦³³\¦hªº±H¥ÍÂε¥·P¬Vª«¡AIgE¤§©Ò¥H
¦s¦bªº¥Dn§@¥Î¡A´N¦b©ó¥D§ð³o¨Ç¯fìÅé¡C·í·P¬Vµo¥Í®É¡AIgE·|¶}©l¤j¶qªº¥X°Ê¡A¶e¨ì³o¨Ç¥~«Iª«¡A¨Ã¥B©M¥Ö½§¼h¤ºªº¡u¥¨¤j
²ÓM¡v(mast cells)¤Wªº¨üÅéµ²¦X¡C
¥¨¤j²ÓM¬O¤HÅé²£¥Íµoª¢¤ÏÀ³ªº¥Dn¨¤¦â¡A¦h¦s¦b©ó¥Ö½§¼h¡A·íIgE©Ô¨ì¥~¨Ó·P¬Vª«ªº§Üì(antigen)¸g¥Ñ©M¥¨¤j²ÓMªº¨üÅé
(receptor)¡AºÙ¤§ Fc£`RI¡A²£¥Í±µÄ²«á¡A¥¨¤j²ÓM´N¶}©l¬¡¤Æ¡A¦b§Üì¥æ¤e³s±µ«á(Crosslink)¡A¥¨¤j²ÓM¶}©l¬¡¤Æ¡A²£¥Í¦UºØ
Äè¼Äª«½è¡A¥]¬A²Õ´Ói¡B¨x¯Àµ¥¡A·í¥¨¤j²ÓM±N³o¨Çª«½èÄÀ©ñ¥X¨Ó®É¡A¤]´N¬O¬°¤°»ò§Ų́Å馳µoª¢²{¶Hªºì¦]¡C¦¹¥~¡A¶ÝÆP©Ê
²ÓM¡A¬O©M¥¨¤j²ÓM©Ê½è¬Û¦üªº§@¥Î¡A¤]¦³Fc£`RI¨üÅé¡A¥u¤£¹L¥¦¬O¦b¦å²G¤º¬y°Êªº¡C
¹L±Ó²{¶H¥ÑIgE©Ò³y¦¨¡A´î¤ÖÅ餺IgEªº¶q´N¯à¦³®Ä´î½w¯gª¬¡Aomalizumab¯à³o»ò¦³®Ä´N¬O¥¦¯à¨³³tªº¤¤©M¦å²G¸ÌªºIgE¡A
Åý³o¨ÇIgE¤£·|¦A¸ò¨üÅéµ²¦X¡A¤£·|¦A«ùÄòªº²£¥Í¹L±Ó¤ÏÀ³¡C
¤¤©M¤§«áÅ餺ÁÙ¬O·|Ä~Äò¥Í¦¨IgE¡A©Ò¥Hn2~4¶gÄ~Äòª`®g¡A¤~¯à±±¨î¯f±¡¡C
·íÅ餺IgE¤Ó°ª®É¡AomalizumabµLªk§¹¥þ¤¤©M¦å²G¸ÌªºIgE¡A¦]¬°¤~·|³]©w¨Ï¥Î½d³ò30~1300IU/mL¡A
¶W¹L1300IUªº¯f±w¤£·|¨Ï¥Îomalizumab¡A
AD¯f¤HªºIgE¦³¨Ç³£«D±`°ª¡A¬Æ¦Ü¨ì¤W¸U¡A¥Îomalizumab¬°¦ó¦³®Ä?±À´úªº¾÷¨î¥i¯à¬OIgE:omalizumab immune complexes¡A
³o¨ÇIgE-omalizumabµ²¦Xª«¦bÁÙ¦b¥NÁ±¼¤§«e¡A¦bÅ餺¦³¹³¹L±Óì²M°£¾¯ªº¥\¯à¡A
¦]¬°¹L±Óì³QIgEµ²¦X¤F¡A¦ý¤S¤£¯à¸ò¨üÅéµ²¦X¡A©Ò¥H¤£·|¤Þ°_¹L±Ó¤ÏÀ³¡A
·íµM³o¬O±À´úªº¡A«Ý½T»{¡C
FB825¸òQuilizumab³£¬O°w¹ïC£`mX¡A¤]ºÙ§@M1¡¦ªº°Ï°ì¡A³o¬O¦b½¤«¬IgE B²ÓM¤Wªº¤@Ӱϰì¡A¦å²G¸Ìªº¤Àªc¥X¨ÓªºIgE´N¨S¦³³o
¤@³¡¤À¡C
oncohemakey.com/biology-of-the-b-lymphocyte/
¬Ý¹Ï8.1
¦¹¬°B²ÓM¤À¤Æªº¹Lµ{¡AB²ÓM¦¨¼ô¨ì³Ì«áÅܦ¨¼ß²ÓM(plasma cell)¡A¼ß²ÓM¬OÅ餺¥Í¦¨§ÜÅ骺²ÓM.
¤À¤Æ¨ìmemory Bªº®ÉÔ¡A²ÓMªí±ÁÙ¦³½¤«¬ªºIg, ¦pIgA, IgG, IgE,
FB825¸òQuilizumab°w¹ïªº³£¬O±a¦³½¤«¬IgEªºB²ÓM¡A©Ò¥H±þ±¼±a¦³½¤«¬IgEªºmemory B¤§«á´N¤£·|¥Í¦¨IgE¼ß²ÓM¡A¶i¦Ó´î¤ÖIgEªº¥Í¦¨¡C
¤@¼Ë¬O´î¤ÖIgE¦ý¾÷¨î¬O¤£¦Pªº¡A¦b¯S©wIgE¿@«×¤Uomalizumab¥i¥H§â즳ªºIgE³£²M°£±¼¡A¦pªG¬O«D±`°ªIgEªº¡A
¥i¯à¤]¦³immune complexesªºÀ°§U¯à²M°£¹L±Óì¡A¦]¦¹¯gª¬¦³§ïµ½¡C
FB825¸òQuilizumab¯àªý¤î·s¥Í¦¨IgEªº¸ô®|¡A¦ýÅ餺즳ªºIgE¨Ã¤£·|²M°£¡A
³¡¤À²£¥ÍIgEªº¨Ó·½³Qªý¤î¤F¡A¦ý즳ªºIgEÁÙ¬O¦³¯à³y¦¨¹L±Ó²{¶Hªº¼Æ¶q¡A
¼ß²ÓM¦³long-live»Pshort-live 2ºØ¡Aµu©Rªº·íµM¤ñ¸û§Ö¦º±¼¡A«áÄò¤£¼vÅT¡A
¦ýlong-liveªº¼ß²ÓMFB825¸òQuilizumab±þ¤£±¼¡A³o¨Ç¥i¯àÁÙ¬O·|«ùÄò²£¥Í·|»{¹L±Ó쪺IgE¡A
¦Ó¥BÁÙ¦³±qIgG memory BÅܦ¨IgE memory Bªº¸ô®|¡A©Ò¥HIgE¦³¤U°¦ý¯gª¬¨S¦³§ïµ½¡C
IgE¦³»{¹L±Óì»P¤£»{¹L±Ó쪺¡A·|»{¹L±Ó쪺IgE¥i¯à¦û¥þÅéIgEªº´X%¦Ó¤w¡A¦ý³o´X%ªºIgE´N¯à³y¦¨¹L±Ó¯e¯f¡C
OmalizumabÁöµM¤]±þ¤£±¼long-live IgE¼ß²ÓM¡A¦ý¥¦¯à¨³³t¦³®Ä°§C¦å²G¤¤ªºIgE¡A´N¬O¦³®Ä¡C
FB825®ÄªG¤ñ¸û¦n?¥u¾a¤½¥qªº§ë¼v¤ù¬O¬Ý¤£¥X¯uªºµ²ªG¡ARoche°µ§¹Á{§É³£µopaper¸Ô²Ó»¡©ú¡A
FB825ªºµ²ªG¦bþ?¦³´X¤ÀÃÒ¾Ú»¡´X¤À¸Ü¡A§Ú¼gªºªF¦è¤£·|Åý§A·Q¶RªÑ²¼¡A¤£·|Åý§A½ß¿ú¡A
§Ú¤]»¡¤F¡A¤G´Áµ²ªG¥X¨Ó¦A»¡¡A¤Ó¦»¡¦³¦h¦n¦h¦n³£¬OªÅ½Í¡A
²³¦h®ø®§¸ÌÁÙ¬On²z©Êªº§PÂ_¤ÀªR¡A¦³¨Ç¤H¨S¦³¬ÛÃöI´º¡A
µLªk¤ñ¸û¸Ô²Óªº¤F¸ÑÃIJz¾÷¨î¡A¥ú¾a®ø®§±¨Ó¨M©w¡A¹ê¦b¬O¥Rº¡·ÀI¡A
ÁöµM»¡°ª·ÀI°ª³ø¹S¡A¦Û¤v²z¸Ñ§¹¨M©w¦Û¤vªº§ë¸ê¡A¦p¦¹¦Ó¤w¡C
¥H¦ûÀù¯gÃĪ«¥«³õ³Ì¤jÀYªºÃ¹¤ó,»¡¤£©w¦³¿³½ì¬Û¤¤ªº¬O¬u²±¿W¨B¥þ²y¤§¸~½F·F²ÓM°ö¾i¡B·sÃÄ¿z¿ï¥¥x
ù¤ó2´Á°µ§¹¤£°µ¤F
¬O§_·|ª½±µ¨ÓÃöª`®ÄªG¸û¦nªºFB825
¬J¬O«O±K¨óij¦ÛµM¥]§tñ¬ù¹ï¶H
«ç¥i¯à¦^µª§A
¦³Ãø«×°Ú,ªB¤Íªº¦P¾Ç¥h¦~¤U¥b¦~¤wÂ÷¶}¤F¦¹¤½¥q
³Ò±z¦V¤½¥q±´¸ß©³¤U·s»D¨Æ¥óñ´»CDA¦³¥]§tù¤ó?
¦³«h§ó¥¿±¼ÖÆ[
2017-01-12 01:10¸gÀÙ¤é³ø
¤p¼¯¥ÍÂå¦~·|¡A¥x¼t¨ü«C·ý¡C¥x¼t°Ñ¥[¼¯®Ú¤j³q°ê»Ú¥ÍÂå¦~·|¡]J.P. Morgan Healthcare Conference¡^¶Ç¨Ó³ß°T¡A¥]¬Aù¤ó¡B¼b¥Í¡B§¨Ó¡B¿ÕµØµ¥°ê»Ú¤@½u¤j¼t¶}¥X±ø¥ó¡A±N§ÞÂà¥x¼t§ÜÅéÃIJ£«~¡A¨ä¤¤¬u²±¡B¦X¤@µ¥¤½¥qªº²£«~§Þ³N¸ß°Ý«×°ª
«á¨Ó¤½¥q¼á²M»¡©ú:¥»¤½¥q¤w»P¦h®aÃļtñ´»CDA¡A¬ÛÃö¨Æ©y§¡¶·¿í¦u«O±K¨óij
1.Anti-IgEÃĪ«ªvÀø¡uºC©ÊëC³Â¯l¡vªº¾÷¨î±´°Q
Xolair ªº§@¥Î¦b©ó¤¤©M¤HÅ餺ªº§K¬Ì§ÜÅéIgE¡C¾ãÓ¥Ö½§¾Ç»PÁ{§É§K¬Ì¾Ç¬É¹ïXolair¬°¦ó¯àªvÀøCSU¡uºC©ÊëC³Â¯l¡v·P¨ì¤£¸Ñ¡Chttp://www.genomics.sinica.edu.tw/index.php/tw/news/news-archives/429-anti-ige
2.http://www.e-jmii.com/article/S1684-1182(11)00267-2/pdf
......IgE levels and eosinophil percentages are not good indicators for a prolonged course
of urticaria(ºC©ÊëC³Â¯l). (AD±wªÌ»PIgE levels°ª«×¦³Ãö)
http://www.e-jmii.com/article/S1684-1182(11)00267-2/pdf
FB825»PQuilizumabªºÃĪ«¾÷¨î±z¤w§¹¥þºN²M?
«¥µù¥U½s¸¹¡G10144700,±z¦«¥´X¸¹.
±zªº¨¤À¤£¥~3ºØ¥i¯à©Ê:¬u²±Â÷¾û¤u/¥Ñ·RÂà«ë¦a§ë¸ê¤H/¨ä¥L?
¦pªG¬u²±¦b¦¨Ç¦~ªº¤¤°ª»ù¦ì,±zªº¨¥½×«¥¯à»{¦P!
¦Ó©Ò¶Kªº¬ã¨s³ø§i¦®¦bªí¹FAD¤¤««×±wªÌ(extrinsic¥~¦]©Ê)»P°ªIge¤ô¥¤GªÌ¶¡ªºÃö³s©Ê¤ñQuilizumabÁ{§ÉªºAllergic asthma; Allergic rhinitis; Urticaria¶¡§ó©úÅã!
§Y«KµLªk§¹¥þ¤¤©MIgE«oÁÙ¬O¦³¯f±w¦³§ïµ½?
OmalizumabªºÃIJz¾÷¨î¸òFB825ªº¤£¦P¦bþ?
¬Ý±o¥X¨Ó,§A¹ïFB825«Ü¦³«H¤ß
·sÃij̫á¯à¦¨¥\ªº¯uªº¤£¦h
¤]§Æ±æ¤½¥q¤£nÅý§ë¸ê¤H¥¢±æ
³Ì«á´£¨Ñ¤G½g³ø§i¼fµøAD±wªÌtotal Ige°40~50%¯gª¬·|¤£·|§ïµ½?
¥t¥~¥þ²y¿W¨B±M§Q¤§¸~½F·F²ÓM°ö¾i»P¿z¿ï¥¥x·|¤£·|¤Þ°_°ê»Ú¤jÃļtª`·N?
1. 2012¦~±i¤l¤å
Among patients with atopic dermatitis, the proportion with IgE above 700 IU/mL is much larger than that for adult allergic asthma: it is common to find atopic dermatitis patients with serum IgE even higher than 10,000 IU/mL.....dermatitis, the IgE levels are too high to be neutralized by affordable doses of omalizumab. (¥xÆW¹L±Ó®ð³Ý±wªÌallergic asthma¥´1°womalizumab¬ùNT$15000)
http://www.sciencedirect.com/science/article/pii/S102781171200095X
2.·Ó¤ù²³æ©öÀ´! 2017 April
¹ÏA /B total Ige±q17,183 IU/mL°¨ì11,983 IU/mL(¬ù°30%).
http://www.mdedge.com/cutis/article/136166/atopic-dermatitis/severe-refractory-atopic-dermatitis-elevated-serum-ige
«ù¦³1000±i¥H¤W¤jªÑªF±q¥¼¦³°Ê§@
¤W©P¬ðµM¼W¥[7¦Ê¦h±i
³o.........
¬Ý¨ÓªÑ»ùªu¸ô¯}©³ªºì¦]
¬O¦¦³¤Hª¾¹DFB825¦¨¥\¾÷²v§C
¤~ª¾¹D¦Û¤v¤Ó¹à¤F
¬Ý³ø¯Èª±ªÑ²¼
«ç»ò¦ºªº³£¤£ª¾¹D
³y¦¨¦å²G¸ÌIgE¿@«×¦^´_ªº³t«×¤ñXOLAIRÁÙ§Ö¡A¬Û¸û¤§¤U´N¤ñ¤£¹LXOLAIR¡C
UB221»PCD23¤W±ªºIgE§@¥Î¡A¬O§_¯à§ó¥[´î¤ÖIgEªº¥Í¦¨¡A¯uªº¨S°µÁ{§É¤£ª¾¹D¡A
«ù¥¬Ý«Ý§a
UB-221¨ã¦³¤£¦P©óXolair®ªº§@¥Î¾÷¨î¡A°£¤F¥i¥H¤¤©M¤Þµo¹L±Ó¤ÏÀ³ªº¥Dn¤À¤lIgE¡A¤]¥i³z¹L»P(CD23)¨üÅé¤WªºIgEµ²¦X®ÄÀ³
MedImmuneªºmedi4212¤¤©MIge±j©óXOLAIR 10¿¤S¦p¦ó? SAE¹L¤£¤FÃö´N¬O¥¢±Ñ¦¬³õ,«öC¤jªº±À²zì«h UB-221¤]¤£®e¼ÖÆ[???
MEDI4212 potently inhibited responses through Fc£`RI and also prevented the binding of IgE to CD23. When used ex vivo at identical concentration, MEDI4212 depleted free-IgE from human sera to levels ~1 log lower than omalizumab
https://kclpure.kcl.ac.uk/portal/en/publications/a-novel-igeneutralizing-antibody-for-the-treatment-of-severe-uncontrolled-asthma(19cb9e9d-0e97-4b72-bfc7-6fcd88f4f1ef).html
¬u²±±ÂÅvFB825®É¡AUB221ÁÙ¨S°µ¦n¡A
FB825¦³¿W¯S©Ê¡A°£¤FROCHE¨S¦³¨ä¥¦¤H¦³¡A
UB221±«e¦³XOLAIR³o®y¤j¤sÀY¡An¶W¶V¥¦¤£¬O³o»ò®e©ö¡A
¦Ó¥BÁÙ¦³¨ä¥¦Ävª§ªÌ¤]¦b±Æ¶¤¤F¡C
UB221»PXOLAIR³£¬O°w¹ïfree IgE¡A
ÁöµMUB221ÁÙ¦³¤£¦Pªº¯S©Ê¡A¦¹¯S©Ê¦³¥i¯à¥h°§CIgEªº¥Í¦¨¡A
·íµM³o¥u¬O²z½×¤W¡A¹ê»Ú¤W·|¤£·|¤ñXOLAIR±j¡A³oÓ¤j·§n§¹¦¨Á{§É¤~¯à±o¨ìµª®×¤F¡C
Áp¥ÍÃĦ³¿³½ì·íµM´N§ÞÂà¡A¦pªG¨S¤H¦³¿³½ì´N¥u¬O©ñµÛ¡A¤£·|¦Û¤vµo®i¡C
FB825ªº½T¤]¦p¹w´Á¯à±þ±¼½¤«¬IgEªºB²ÓM¡A¶i¦Ó´î¤Ö²£¥ÍIgE¡A
¦ý¦³¨Ç¬¡«Ü¤[ªºIgE¼ß²ÓM·|¤@ª½²£¥ÍIgE¡A¦å²G¤¤ªºIgE¤U°¤FÁÙ¬O¤£ºâ§C¡C
¦bIgE¤£¬O«Ü°ªªº¯f±w¨Ó»¡¡A¨Ï¥ÎXolair¥i¥H°¨¤W°§C¦å²G¤¤ªºIgE¡A
ÁöµMn«ùÄò¬I¥´¡A¦]¬°¯à¦³®Äªº²M°£IgE¡A©Ò¥H¯gª¬¯à±o¨ì§ïµ½¡C
FB825n°w¹ï°ªIgEªº¯f±w¡A°²³]¬O1500IU¥H¤W¡A´î¤Ö50%ÁÙ¬O¦³750IU¡A
Å餺³oºØ¿@«×ªºIgE¥i¯àÁÙ¬OÅý¯gª¬«ùÄò¡A¨Ã¨S¦³§ïµ½¡A
¦óªp¦³¨Ç¯f¤HªºIgE¬O§ó°ªªº¡A³æ¾a³o¼Ë´Nn¦³Àø®Ä¬O¤£¬O¨º»ò®e©ö¡A
¾Ö¤j¡A
respiratory-research.biomedcentral.com/articles/10.1186/s12931-016-0347-2
Quilizumab¦b¤ñ¸ûÄY«ªº®ð³Ý¤¤¨Ã¨S¦³±o¨ìÀø®Ä¡AFB825¤]¤£·|¥h°µ³o¼Ëªº¹Á¸Õ¡A
©Ò¥H¥u·|¬D¨ä¥¦¾AÀ³¯g¡A©Î¬On¥h¥Ó½Ð©t¨àÃÄ¡A¨ä¥¦¾AÀ³¯g¤£¤@©w¦³®Ä¡A©t¨àÃĤ@¦~ªº¥«³õ¨Ã¤£¤j¡A¦Ó¥B°w¹ï°ªIgE¯f±wÁÙ¬O¹J¨ì¦P¼Ëªº°ÝÃD¡C
¥²³Ó¤j¡A
²q´ú¤£¬O½Í±ÂÅv¤~©ì©µÁ{§É®Éµ{¡A¦ÂI°µ§¹Á{§É¤~¯à¦ÂI¥X°â¡A
«e´£¬On¦³®Ä¡A¬Ý¨ìRocheªºµ²ªGÀ³¸ÓÅý¬u²±¦b¦Ò¼{n¤£n°µ¤U¥h¤~ºC¤F¸}¨B¡A
°Ñ¦ÒRocheªºqulizumab¤ñ¸û±µªñFB825ªºÃIJz¾÷¨î¡C
quilizumab¤£Ä~Äò¤F¡AFB825ÀY³£¬~¤F¤]¥u¯àÄ~Äò¤U¥h¡A
¤@¨Ó¬O¨S°µ¨ì³Ì«á·íµM¤£ª¾¹Dµ²ªG·|¦p¦ó¡A¤G¨Ó¬O²{¦b°±¤F´N¬O»{¿é¡A
¤]¨S¦³¸ÜÃD¥iª£¡A©Ò¥H¤G´ÁÁÙ¬OnÄ~Äò°µ¡C
¤~¤@´Á¹L¤F¤½¥q´N«æµÛ±ÂÅv
®ö¶O§Ö1¦~ªº®É¶¡
®ð³Ý¯f¥ÎÃÄÄvª§¤Ó¿E¯P¡A§äÄvª§¸û¤ÖªºÂÅ®üÀ³¸Ó¬O¤½¥qªº
µ¦²¤¡A§Úªº¬ÝªkFB825©Î³\¦³½Í±ÂÅv¦]¦¹©ì©µÁ{§É®Éµ{¡A
¥i¯à¬O³Ì«á¨S½Í¦¨¡A²{¦b¤~¶}©l°µÁ{§É¡A¤£¹LºCÁ`¤ñ¥¢±Ñ
¦n¡C